#VisualAbstract: Cabozantinib Improved Progression-Free Survival in Advanced Neuroendocrine 2m -m Tumors
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: neuroendocrine tumor
177Lu-Dotatate plus octreotide was not superior in overall survival compared to octreotide alone for neuroendocrine tumours
1. The median overall survival for patients receiving177Lu-Dotatate and intramuscular, long-acting octreotide was 47.0 months and 36.3 months respectively 2. ...
Radiolabeled somatostatin analogue linked with improved survival in neuroendocrine tumors
1. 177Lu-Dotatate, a radiolabeled somatostatin analogue, was associated with increased progression-free survival and decreased overall mortality compared to standard therapy ...
Neuroendocrine tumor marker pancreastatin may be predictive of survival
Image: CC/Wiki 1. High pre- and post-operative levels of pancreastatin were significantly correlated with shorter progression free survival (PFS) and ...